NASDAQ: KYNBKyntra Bio Inc Stock
$7.63+0.08 (+1.06%)
Updated Jul 2, 2026
KYNB Price
$7.63
Fair Value Price
N/A
Market Cap
$30.89M
52 Week Low
$5.37
52 Week High
$12.60
P/E
0.19x
P/B
-0.71x
P/S
3.69x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.44M
Earnings
$163.62M
Gross Margin
40.7%
Operating Margin
2,318.26%
Profit Margin
2,199.4%
Debt to Equity
-2.72
Operating Cash Flow
-$21M
Beta
1.45
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
KYNB Overview
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KYNB's potential to beat the market
- KYNB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KYNB
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important KYNB news, forecast changes, insider trades & much more!
KYNB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KYNB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KYNB is good value based on its earnings relative to its share price (0.19x), compared to the US market average (8.54x)
P/E vs Market Valuation
KYNB is good value based on its earnings relative to its share price (0.19x), compared to the US Biotechnology industry average (17.59x)
P/E vs Industry Valuation
KYNB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more KYNB due diligence checks available for Premium users.
Valuation
KYNB fair value
Fair Value of KYNB stock based on Discounted Cash Flow (DCF)
Price
$7.63
Fair Value
$10.60
Undervalued by
28.05%
KYNB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.19x
Industry
17.59x
Market
8.54x
KYNB is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
KYNB is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
KYNB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.71x
Industry
5.6x
KYNB's financial health
Profit margin
Revenue
$3.7M
Net Income
-$15.2M
Profit Margin
-406.6%
KYNB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KYNB's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$109.6M
Liabilities
$118.9M
Debt to equity
-2.72
KYNB's short-term assets ($101.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KYNB's short-term assets ($101.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KYNB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KYNB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.9M
Investing
$3.0M
Financing
-$7.0k
KYNB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KYNB vs Biotech Stocks
Kyntra Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.